Oncology

Long-term Management of Advanced CRC: An Interactive Patient Case

Which clinical decisions will you make?

Assoc. Prof. Gerald Prager

Assoc. Prof. Joleen Hubbard

Publication Date

Jul 2023

* To replay the media content and watch again, please refresh your screen

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

In this interactive patient case study, developed by Assoc. Prof Gerald Prager and Assoc. Prof. Joleen Hubbard, you'll learn about the management of colorectal cancer (CRC) to achieve a long-term response. As you work through the two patient cases, you'll make treatment decisions at key points and receive feedback on your choices, with references to supporting data.

After taking part, you'll understand:

How to view CRC treatment as a continuum of care
What to consider when making treatment decisions
Which treatment options are available for CRC patients 3rd line and beyond

Take the interactive patient case programme below or follow the link to take the accredited e-learning to count towards your CME credit.

Clinical Takeaways

Treatment of advanced colorectal cancer (CRC) should be considered as a continuum of care and patients should be offered as many life prolonging therapies as possible
Decision-making at each stage of therapy should consider patients' suitability and tolerability, tumour biomarkers and prior exposure to chemotherapies and/or targeted agents
There are a number of treatment options for CRC patients third-line and beyond which should be considered such as regorafenib, trifluridine/tipiracil as well as consideration of clinical trials and rechallenge with chemotherapy or anti-EGFR

This programme is endorsed by:

Digestive Cancers Europe (DiCE) is a European non-profit umbrella organisation of nearly 40 national Member Organisations across Europe representing patients with digestive cancers – colorectal, gastric, liver, oesophageal, pancreatic, and rare digestive cancers. DiCE is committed to advancing diagnosis and medical treatment, advocating high standards in clinical practice, education, and research, and supporting patient care for a better quality of life. DiCE's vision is to see fewer people in Europe suffering from digestive cancers.

Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).

Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, BMS, Incyte, Merck Serono, MSD, Servier, Takeda

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota. She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network.

Assoc. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory boards: Bayer, Merck, BeiGene, Incyte

Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche